2014 – Virobay to present data on two Cathepsin S inhibitor programs in neuropathic pain and Alzheimer's disease at the 2014 Society for Neuroscience Annual Meeting more
2014 – Virobay completes $8 million Series B preferred stock financing more
2014 – Virobay announces the appointment of James Welch as Chief Financial Officer more
2014 – Virobay appoints Thomas J. Dietz, Ph.D. to the Virobay Board of Directors more
Virobay is investigating promising new approaches for the treatment of neuroapathic pain, autoimmune diseases, liver fibrosis, and cancer.
|Psoriasis - LEO Pharma||X|